The return to normal operations within the US Food and Drug Administration'sCenter for Biologics Evaluation and Research next year will require eliminating backlogs and resuming regular meeting schedules.
CBER director Peter Marks said the center’s theme for the remainder of 2022 is response and recovery as it tries to move beyond COVID-19 as a primary focus. He estimated...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?